Trimesta is being tested with Teva's Copaxone. Copaxone contributes $4 billion in sales per year and goes off patent this year. SYN's patent covers both drugs. The only way Teva can protect their $4B/year baby is by buying Trimesta . If they don't buy Trimesta Copaxone will be marginalized by the hovering generics. So if Trimesta works look for a very big deal between SYN and TEVA. We have to ask ourselves what would one pay to protect a $4 billion/year franchise? $8B-12B? On the other hand If Trimesta doesn't work, then there's no deal. April's announcement is a true binary event. And I love the odds of it working and a buyout happening shortly thereafter.
Very true & an excellent point for the SYN bulls. Owning a US patent that includes claims for use of Trimesta in combination with Copaxone should turbocharge the runup to April 28 AAN presentation imo.